Amarin Corp Plc (AMRN)

[rfj1862]

I'm confident you're correct, rfj. I recall another student at the Kennedy School undertaking an analysis on the cost-savings of different health care interventions that we might pay for as a society. Measures that people think of as saving tons of money--smoking cessation, for example--don't pencil out. Many adult-onset interventions don't pencil out, because they allow us to live longer in retirement, spending society's wealth on our Social Security and medicare/medicaid.

Spending on kids pays off well; you don't want to invest in kids and have them depart before they start paying taxes.

There can be savings if you have a better treatment that allows someone who would otherwise be disabled and need more expensive care to be healthier and need less or no care as a consequence.

It's not just the cost to society. The cost to prevent one event is higher than the cost of the event itself.

The thing the people who are arguing with me don't get is that that is okay. Nobody expects a new drug to result in savings. What they do expect is for it to be cost effective, which Vascepa is, in spades.